参考文献/References:
[1] Chen QH,Lu L,Qi GR,et al. [Susceptibility of patients with congenital heart disease to pulmonary hypertension at a high altitude][J]. Zhonghua Yi Xue Za Zhi,2011,91(44):3120-3122.
[2] Zhao L,Chen L,Yang T,et al. Birth prevalence of congenital heart disease in China,1980－2019:a systematic review and meta-analysis of 617 studies[J]. Eur J Epidemiol,2020,35(7):631-642.
[3] van der Bom T,Bouma BJ,Meijboom FJ,et al. The prevalence of adult congenital heart disease,results from a systematic review and evidence based calculation[J]. Am Heart J,2012,164(4):568-575.
[4] Chen QH,Wang XQ,Qi SG. Cross-sectional study of congenital heart disease among Tibetan children aged from 4 to 18 years at different altitudes in Qinghai province[J]. Chin Med J(Engl),2008,121(24):2469-2472.
[5] Galie N,Manes A,Palazzini M,et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome[J]. Drugs,2008,68(8):1049-1066.
[6] Duffels MG,Engelfriet PM,Berger RM,et al. Pulmonary arterial hypertension in congenital heart disease:an epidemiologic perspective from a Dutch registry[J]. Int J Cardiol,2007,120(2):198-204.
[7] Diller GP,Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease[J]. Circulation,2007,115(8):1039-1050.
[8] 郭妍,秦永文. 先天性心脏病合并肺动脉高压住院构成及临床特征分析[J]. 第二军医大学学报,2008,29(3):306-310.
[9] Xu XQ,Jing ZC. High-altitude pulmonary hypertension[J]. Eur Respir Rev,2009,18(111):13-17.
[10] Groves BM,Droma T,Sutton JR,et al. Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m[J]. J Appl Physiol (1985),1993,74(1):312-318.
[11] Grocott M,Montgomery H,Vercueil A. High-altitude physiology and pathophysiology:implications and relevance for intensive care medicine[J]. Crit Care,2007,11(1):203.
[12] Peng Y,Cui C,He Y,et al. Down-regulation of EPAS1 transcription and genetic adaptation of Tibetans to high-altitude hypoxia[J]. Mol Biol Evol,2017,34(4):818-830.
[13] Petousi N,Croft QP,Cavalleri GL,et al. Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia[J]. J Appl Physiol(1985),2014,116(7):893-904.
[14] Simonson TS,McClain DA,Jorde LB,et al. Genetic determinants of Tibetan high-altitude adaptation[J]. Hum Genet,2012,131(4):527-533.
[15] Jeong C,Alkorta-Aranburu G,Basnyat B,et al. Admixture facilitates genetic adaptations to high altitude in Tibet[J]. Nat Commun,2014,5:3281.
[16] Bigham A,Bauchet M,Pinto D,et al. Identifying signatures of natural selection in Tibetan and Andean populations using dense genome scan data[J]. PLoS Genet,2010,6(9):e1001116.
[17] Simonson TS. Altitude adaptation:a glimpse through various lenses[J]. High Alt Med Biol,2015,16(2):125-137.
[18] 梁贞. 西藏不同海拔各慢性高原病的患病率调查与研究[D]. 拉萨:西藏大学,2021.
[19] Morrell NW,Sarybaev AS,Alikhan A,et al. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders[J]. Lancet,1999,353(9155):814.
[20] Aldashev AA,Sarybaev AS,Sydykov AS,et al. Characterization of high-altitude pulmonary hypertension in the Kyrgyz:association with angiotensin-converting enzyme genotype[J]. Am J Respir Crit Care Med,2002,166(10):1396-1402.
[21] Kojonazarov B,Isakova J,Imanov B,et al. Bosentan reduces pulmonary artery pressure in high altitude residents[J]. High Alt Med Biol,2012,13(3):217-223.
[22] Miao CY,Zuberbuhler JS,Zuberbuhler JR. Prevalence of congenital cardiac anomalies at high altitude[J]. J Am Coll Cardiol,1988,12(1):224-228.
[23] Morton SU,Quiat D,Seidman JG,et al. Genomic frontiers in congenital heart disease[J]. Nat Rev Cardiol,2022,19(1):26-42.
[24] 刘世明,李愈娴,路霖,等. 高原地区先天性心脏病基因突变的遗传与表观遗传学研究[J]. 高原医学杂志,2022,32(3):10-14.
[25] 李爽林. FOXP1基因和FFAR4基因多态性与高原藏族先天性心脏病的相关性研究[D]. 西宁:青海大学,2021.
[26] Yang W,Bai J,Song X,et al. CCN1 gene polymorphisms associated with congenital heart disease susceptibility in Northwest Chinese population from different high-altitude areas[J]. Environ Sci Pollut Res Int,2021,28(40):56927-56937.
[27] Beall CM,Cavalleri GL,Deng L,et al. Natural selection on EPAS1(HIF2α) associated with low hemoglobin concentration in Tibetan highlanders[J]. Proc Natl Acad Sci U S A,2010,107(25):11459-11464.
[28] Pan H,Chen Q,Qi S,et al. Mutations in EPAS1 in congenital heart disease in Tibetans[J]. Biosci Rep ,2018,38(6):BSR20181389.
[29] Arias-Stella J,S aldana M. The terminal portion of the pulmonary arterial tree in people native to high altitudes[J]. Circulation,1963,28:915-925.
[30] Naeye RL. Children at high altitude:pulmonary and renal abnormalities[J]. Circ Res ,1965,16:33-38.
[31] Hasan A. Relationship of high altitude and congenital heart disease[J]. Indian Heart J,2016,68(1):9-12.
[32] Wu W,Li Y,Xu DQ. Role of ROS/Kv/HIF axis in the development of hypoxia-induced pulmonary hypertension[J]. Chin Med Sci J,2017,32(4):253-259.
[33] 杨生岳,冯恩志,闫自强,等. 高原肺水肿患者肺血管活性因子水平变化及其与肺动脉高压的关系[J]. 中华肺部疾病杂志(电子版),2011,4(1):31-35.
[34] Yao J,Fang X,Zhang C,et al. AstragalosideⅣattenuates hypoxia?induced pulmonary vascular remodeling via the Notch signaling pathway[J]. Mol Med Rep,2021,23(1):89.
[35] Liu W,Zhang Y,Lu L,et al. Expression and correlation of hypoxia-inducible factor-1α (HIF-1α) with pulmonary artery remodeling and right ventricular hypertrophy in experimental pulmonary embolism[J]. Med Sci Monit,2017,23:2083-2088.
[36] Chen L,Ren L,Song H,et al. Triflavones from selaginella doederllein inhibited hypoxia-induced,pulmonary vascular remodeling through PI3K/Akt[J]. Altern Ther Health Med,2021,27(6):34-39.
[37] Li YX,Run L,Shi T,et al. CTRP9 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation,apoptosis and migration via TGF-β1/ERK1/2 signaling pathway[J]. Biochem Biophys Res Commun,2017,490(4):1319-1325.
[38] Veith C,Schermuly RT,Brandes RP,et al. Molecular mechanisms of hypoxia‐inducible factor‐induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension[J]. J Physiol,2016,594(5):1167-1177.
[39] Stockmann C,Fandrey J. Hypoxia-induced erythropoietin production:a paradigm for oxygen-regulated gene expression[J]. Clin Exp Pharmacol Physiol,2006,33(10):968-979.
[40] Sydykov A,Maripov A,Kushubakova N,et al. An exaggerated rise in pulmonary artery pressure in a high-altitude dweller during the cold season[J]. Int J Environ Res Public Health,2021,18(8):3984.
[41] Humbert M,Kovacs G,Hoeper MM,et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J,2022,43(38):3618-3731.
[42] Sneeringer MR,Vadlaputi P,Lakshminrusimha S,et al. Lower pass threshold (≥93%) for critical congenital heart disease screening at high altitude prevents repeat screening and reduces false positives[J]. J Perinatol,2022,42(9):1176-1182.
[43] León-Velarde F,Maggiorini M,Reeves JT,et al. Consensus statement on chronic and subacute high altitude diseases[J]. High Alt Med Biol,2005,6(2):147-157.
[44] Baumgartner H,de Backer J,Babu-Narayan SV,et al. 2020 ESC Guidelines for the management of adult congenital heart disease[J]. Eur Heart J,2021,42(6):563-645.
[45] 冶敦清. 高原地区先天性心脏病介入治疗方法与疗效分析[J]. 中西医结合心血管病电子杂志,2020,8(25):38-39.
[46] Tefera E,Qureshi SA,Bermudez-Ca?ete R,et al. Percutaneous closure of patent arterial ducts in patients from high altitude:a sub-Saharan experience[J]. Ann Pediatr Cardiol,2015,8(3):196-201.
相似文献/References:
[1]郭琳娟,洪葵.成人先天性心脏病心律失常的诊断和治疗进展[J].心血管病学进展,2015,(6):752.[doi:10.3969/j.issn.1004-3934.2015.06.024]
GUO Linjuan,HONG Kui.Advances in Diagnosis and Treatment of Adult Congenital Heart
Disease with Arrhythmia[J].Advances in Cardiovascular Diseases,2015,(1):752.[doi:10.3969/j.issn.1004-3934.2015.06.024]
[2]朱峰,陈铀.先天性心脏病相关肺动脉高压的治疗进展[J].心血管病学进展,2019,(6):894.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.014]
ZHU Feng,CHEN You.Congenital Heart Disease-related Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):894.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.014]
[3]黄金秋 路发文 赵永康 陈宇雨 史红蕊 王萍 杨菊仙.先天性心脏病患儿营养状况及其危险因素分析[J].心血管病学进展,2020,(12):1324.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.023]
HUANG Jinqiu,LU Fawen,ZHAO Yongkang,et al.Nutritional Status in Children with Congenital Heart Disease and the Influential Factors[J].Advances in Cardiovascular Diseases,2020,(1):1324.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.023]
[4]周玲梅 张文倩 张智伟.体-肺动脉分流术在建立先天性心脏病动物模型中的应用进展[J].心血管病学进展,2021,(7):628.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.013]
ZHOU Lingmei,ZHANG Wenqian,ZHANG Zhiwei.Application Progress of Systemic Pulmonary Arterial Shunt in Animal Model of Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2021,(1):628.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.013]
[5]林锡祥 杨菲菲 陈煦 何昆仑.人工智能赋能医学影像在先天性心脏病医学诊治中的研究进展[J].心血管病学进展,2022,(12):1063.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.002]
LIN Xixiang,YANG Feifei,CHEN Xu,et al.Artificial Intelligence Medical Imaging Technology in Medical Imaging of Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2022,(1):1063.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.002]
[6]刘晓旭 莫绪明.先天性心脏病患儿心肺转流术后肠道损伤机制及治疗进展[J].心血管病学进展,2023,(6):501.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.0005]
LIU Xiaoxu,MO Xuming.Mechanism and Treatment of Intestinal Injury After Cardiopulmonary Bypass in Children with Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2023,(1):501.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.0005]
[7]董捷 杜楚豪 董硕 刘顺 徐海涛 孙阳雪 邹孟轩 孙家树 李守军 杨克明 闫军.Uhl畸形诊断与治疗研究进展[J].心血管病学进展,2023,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.004]
DONG Jie DU Chuhao DONG ShuoLIU Shun,XU HaitaoSUN YangxueZOU MengxuanSUN JiashuLI Shoujun,YANG Keming,et al.Diagnosis and Treatment for Uhls Anomaly[J].Advances in Cardiovascular Diseases,2023,(1):686.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.004]
[8]陈颖慧 冯奕源 冯炜琦 吴逸卓 鲁亚南 于昱.血管发育异常的先天性心脏病患儿中Vav2基因突变的筛查和功能分析[J].心血管病学进展,2023,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.019]
CHEN Yinghui,FENG Yiyuan,FENG Weiqi,et al.Identification and Functional Analysis of Vav2 Novel Variant in Congenital Heart Diseases with Vascular Malformation[J].Advances in Cardiovascular Diseases,2023,(1):757.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.019]
[9]李强强 顾虹.中国儿童肺动脉高压诊治现状[J].心血管病学进展,2024,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.003]
LI Qiangqiang,GU Hong.Current Status of Diagnosis and Treatment of Pulmonary Hypertension in Chinese Children[J].Advances in Cardiovascular Diseases,2024,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.003]
[10]李思聪 罗勤 赵智慧 赵青 柳志红.房间隔缺损相关肺动脉高压机制及治疗进展[J].心血管病学进展,2024,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.004]
LI Sicong,LUO Qin,ZHAO Zhihui,et al.Pathogenesis and Treatment of Pulmonary Hypertension Associated with Atrial Septal Defect[J].Advances in Cardiovascular Diseases,2024,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.004]